On CNBC’s Closing Bell OptionMonster Jon Najarian explained the spike was due to speculation the Botox maker may be acquired by GlaxoSmith Kline
According to Bloomberg, “Allergan call options surged in the first 90 minutes of trading to a record 45,089, or 15 times the four-week average. Calls give the right to buy a security for a certain amount, the strike price, by a given date.”
Glaxo had no comment.
Althouugh it’s widely believed that GSK is the most likely suitor Jon Najarian adds that Baxter, a lesser known health care company, may also be a potential bidder.
And in addition, Najarian has his eye on Seagate. He suggests options activity could signal deal making chatter. And he says, if the firm is an M&A target the “takeout price should be north of $13 double of where the stock is trading right now.”
What does Najarian make of all the options action?
"Investors are coming out of their caves and risk takers are getting back in the game," he says.